FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire2022; 86(1); 59-64;

In vitro antimicrobial activity of equine platelet lysate and mesenchymal stromal cells against common clinical pathogens.

Abstract: Septic arthritis is considered a medical emergency. Disease following bacterial colonization can lead to significant morbidity and mortality and requires costly treatment. Antimicrobial properties of regenerative therapies, including mesenchymal stromal cells and platelet products, have been researched extensively in human medicine. Although fewer studies have been conducted in veterinary species, they have shown promising results. The purpose of this study was to evaluate bacterial suppression by equine platelet lysate (EPL) and adipose-derived mesenchymal stromal cells (ASCs) in vitro. We hypothesized that both products would significantly inhibit the growth of Staphylococcus aureus and Escherichia coli. Pooled blood from 10 horses was used for production of EPL. Mesenchymal stromal cells were isolated from adipose tissue harvested from the gluteal region of 3 horses. The study evaluated 3 treatment groups: 10 × EPL, 1.6 million ASCs, and a control, using an incomplete unbalanced block design with repeated measurements. Optical density readings and colony-forming units/mL were calculated at 0, 3, 6, 9, 12, 18, and 24 hours. Decreased bacterial growth was seen at multiple time points for the S. aureus-ASC and S. aureus-EPL treatments, supporting our hypothesis. Increased bacterial growth was noticed in the E. coli-EPL group, with no difference in the E. coli-ASC treatment, which opposed our hypothesis. A clear conclusion of antimicrobial effects of EPL and ASCs cannot be made from this in vitro study. Although it appears that ASCs have a significant effect on decreasing the growth of S. aureus, further studies are needed to explore these effects, particularly in Gram-positive bacteria. L’arthrite septique est considérée comme une urgence médicale. La maladie consécutive à une colonisation bactérienne peut entraîner une morbidité et une mortalité importantes et nécessite un traitement coûteux. Les propriétés antimicrobiennes des thérapies régénératives, y compris les cellules stromales mésenchymateuses et les produits plaquettaires, ont fait l’objet de recherches approfondies en médecine humaine. Bien que moins d’études aient été menées chez les espèces animales, elles ont montré des résultats prometteurs. Le but de cette étude était d’évaluer la suppression bactérienne par le lysat plaquettaire équin (EPL) et les cellules stromales mésenchymateuses adipeuses (ASC) i n vitro. Nous avons émis l’hypothèse que les deux produits inhiberaient de manière significative la croissance de Staphylococcus aureus et d’Escherichia coli. Un pool de sang de 10 chevaux a été utilisé pour la production d’EPL. Des cellules stromales mésenchymateuses ont été isolées à partir de tissu adipeux prélevé dans la région fessière de trois chevaux. L’étude a évalué trois groupes de traitement : 10 × EPL, 1,6 million d’ASC et un témoin, en utilisant un design en blocs non équilibrés incomplets avec des mesures répétées. Les lectures de densité optique et les unités formatrices de colonie/mL ont été calculées à 0, 3, 6, 9, 12, 18 et 24 heures. Une diminution de la croissance bactérienne a été observée à plusieurs moments pour les traitements S. aureus-ASC et S. aureus-EPL, soutenant notre hypothèse. Une croissance bactérienne accrue a été remarquée dans le groupe E. coli-EPL, sans différence dans le traitement E. coli-ASC, ce qui s’opposait à notre hypothèse. Une conclusion claire des effets antimicrobiens de l’EPL et des ASC ne peut pas être tirée de cette étude in vitro. Bien qu’il semble que les ASC aient un effet significatif sur la diminution de la croissance de S. aureus, d’autres études sont nécessaires pour explorer ces effets, en particulier chez les bactéries à Gram positif.(Traduit par Docteur Serge Messier).
Copyright and/or publishing rights held by the Canadian Veterinary Medical Association.
Get Full Text
Publication Date: 2022-01-04 PubMed ID: 34975224PubMed Central: PMC8697329
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study explores the potential of equine platelet lysate and adipose-derived mesenchymal stromal cells in inhibiting bacterial growth, focusing on Staphylococcus aureus and Escherichia coli. The results partially support the hypothesis, with significant bacterial suppression observed against S. aureus but not E. coli. Further studies are needed to fully understand the antimicrobial effects of these substances.

Study Objective and Hypothesis

  • The primary aim of the research was to investigate the bacterial suppression properties of equine platelet lysate (EPL) and adipose-derived mesenchymal stromal cells (ASCs).
  • The study hypothesized that both EPL and ASCs would significantly inhibit the growth of two common bacteria: Staphylococcus aureus and Escherichia coli.

Research Methodology

  • Blood from 10 horses was pooled to produce EPL, while ASCs were isolated from adipose tissue from the gluteal region of 3 horses.
  • Three treatment groups were created: one with a 10-fold concentration of EPL, the second with 1.6 million ASCs, and a control group.
  • An incomplete unbalanced block design with repeated measurements was used in the experiment.
  • Optical density readings and colony-forming units/mL were recorded at multiple intervals: 0, 3, 6, 9, 12, 18, and 24 hours.

Study Outcomes

  • Evidence of decreased bacterial growth was seen at multiple time points for the S. aureus-ASC and S. aureus-EPL treatments, supporting the research hypothesis.
  • In contrast, increased bacterial growth was noticed in the E. coli-EPL group, contradicting the hypothesis. There was no change observed in the E. coli-ASC treatment, also challenging the study’s prediction.

Conclusions and Further Study

  • No definitive conclusion on the antimicrobial effects of EPL and ASCs could be drawn from this in vitro study.
  • Although the research suggests that ASCs have a significant effect on reducing S. aureus growth, additional studies are necessary to validate and further explore these effects, particularly concerning Gram-positive bacteria such as S. aureus.

Cite This Article

APA
Avellar HK, Lutter JD, Ganta CK, Beard W, Smith JR, Jonnalagadda N, Peloquin S, Kang Q, Ayub K. (2022). In vitro antimicrobial activity of equine platelet lysate and mesenchymal stromal cells against common clinical pathogens. Can J Vet Res, 86(1), 59-64.

Publication

Canadian journal of veterinary research = Revue canadienne de recherche veterinaire
ISSN: 1928-9022
NlmUniqueID: 8607793
Country: Canada
Language: English
Volume: 86
Issue: 1
Pages: 59-64

Researcher Affiliations

Avellar, Haileigh K
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Lutter, John D
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Ganta, Charan K
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Beard, Warren
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Smith, Joseph R
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Jonnalagadda, Naveen
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Peloquin, Sarah
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Kang, Qing
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).
Ayub, Kanwal
  • Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).

MeSH Terms

  • Adipose Tissue
  • Animals
  • Blood Platelets / microbiology
  • Escherichia coli / growth & development
  • Horses
  • Mesenchymal Stem Cells / microbiology
  • Staphylococcus aureus / growth & development

References

This article includes 28 references
  1. Dechant JE, Symm WA, Nieto JE. Comparison of pH, lactate, and glucose analysis of equine synovial fluid using a portable clinical analyzer with a bench-top blood gas analyzer.. Vet Surg 2011;40:811–816.
    pubmed: 21770979
  2. Miagkoff L, Archambault M, Bonilla AG. Antimicrobial susceptibility patterns of bacterial isolates cultured from synovial fluid samples from horses with suspected septic synovitis: 108 cases (2008–2017). J Am Vet Med Assoc 2020;256:800–807.
    pubmed: 32176585
  3. Auer JA, Stick JA, Kümmerle IM, Prange T. Equine Surgery. 5th ed. St. Louis, Missouri: Elsevier; 2019.
  4. Tulamo RM, Bramlage LR, Gabel AA. Sequential clinical and synovial fluid changes associated with acute infectious arthritis in the horse.. Equine Vet J 1989;21:325–331.
    pubmed: 2776718
  5. Schneider RK, Bramlage LR, Moore RM, Mecklenburg LM, Kohn CW, Gabel AA. A retrospective study of 192 horses affected with septic arthritis/tenosynovitis.. Equine Vet J 1992;24:436–442.
    pubmed: 1459056
  6. Gilbertie JM, Schnabel LV, Stefanovski D, Kelly DJ, Jacob ME, Schaer TP. Gram-negative multi-drug resistant bacteria influence survival to discharge for horses with septic synovial structures: 206 cases (2010–2015). Vet Microbiol 2018;226:64–73.
    pubmed: 30389045
  7. Meijer MC, van Weeren PR, Rijkenhuizen AB. Clinical experiences of treating septic arthritis in the equine by repeated joint lavage: A series of 39 cases.. J Vet Med A Physiol Pathol Clin Med 2000;47:351–365.
    pubmed: 11008444
  8. Hardy J. Etiology, diagnosis, and treatment of septic arthritis, osteitis, and osteomyelitis in foals.. Clin Tech Equine Pract 2006;5:309–317.
  9. Lugo J, Gaughan EM. Septic arthritis, tenosynovitis, and infections of hoof structures.. Vet Clin North Am Equine Pract 2006;22:363–388.
    pubmed: 16882480
  10. Robinson CS, Timofte D, Singer ER, Rimmington L, Rubio-Martínez LM. Prevalence and antimicrobial susceptibility of bacterial isolates from horses with synovial sepsis: A cross-sectional study of 95 cases.. Vet J 2016;216:117–121.
    pubmed: 27687937
  11. Shirtliff ME, Mader JT. Acute septic arthritis.. Clin Microbiol Rev 2002;15:527–544.
    pmc: PMC126863pubmed: 12364368
  12. Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: Current status and new perspectives of antimicrobial peptide-based therapies.. Front Immunol 2017;8:339.
    pmc: PMC5371613pubmed: 28424688
  13. Del Fabbro M, Bortolin M, Taschieri S, Ceci C, Weinstein RL. Antimicrobial properties of platelet-rich preparations. A systematic review of the current pre-clinical evidence.. Platelets 2016;27:276–285.
    pubmed: 26763769
  14. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration.. Thromb Haemost 2004;91:4–15.
    pubmed: 14691563
  15. Garbin LC, Olver CS. Platelet-rich products and their application to osteoarthritis.. J Equine Vet Sci 2020;86:e102820.
    pubmed: 32067662
  16. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells.. Cell Med 2012;4:1–11.
    pmc: PMC3495591pubmed: 23152950
  17. Ferris DJ, Frisbie DD, Kisiday JD. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014;43:255–265.
    pubmed: 24433318
  18. Drago L, Bortolin M, Vassena C, Romanò CL, Taschieri S, Del Fabbro M. Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: An in vitro study.. PLoS One 2014;9:e107813.
    pmc: PMC4169456pubmed: 25232963
  19. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets.. Infect Immun 2002;70:6524–6533.
    pmc: PMC132966pubmed: 12438321
  20. Harman RM, Yang S, He MK, Van de Walle GR. Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of bacteria commonly found in skin wounds.. Stem Cell Res Ther 2017;8:157.
    pmc: PMC5496374pubmed: 28676123
  21. Gilbertie JM, Schaer TP, Schubert AG. Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro.. J Orthop Res 2020;38:1365–1374.
    pmc: PMC8018705pubmed: 31922274
  22. Farghali HA, AbdElKader NA, AbuBakr HO. Antimicrobial action of autologous platelet-rich plasma on MRSA-infected skin wounds in dogs.. Sci Rep 2019;9:e12722.
    pmc: PMC6722138pubmed: 31481694
  23. Mariani E, Canella V, Berlingeri A. Leukocyte presence does not increase microbicidal activity of Platelet-rich Plasma in vitro.. BMC Microbiol 2015;15:149.
    pmc: PMC4520275pubmed: 26223356
  24. Yang LC, Hu SW, Yan M, Yang JJ, Tsou SH, Lin YY. Antimicrobial activity of platelet-rich plasma and other plasma preparations against periodontal pathogens.. J Periodontol 2015;86:310–318.
    pubmed: 25345340
  25. Pezzanite LM, Johnson V, Goodrich LR, Dow S. Equine mesenchymal stem cells possess antimicrobial properties.. Vet Comp Orthop Traumatol 2018;31:A1–A25.
    pubmed: 0
  26. Krijgsveld J, Zaat SA, Kuijpers AJ, Engbers GH, Feijen J, Dankert J. Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy.. Washington, D.C: American Society for Microbiology; 1998.
  27. Yeaman MR. The role of platelets in antimicrobial host defense.. Clin Infect Dis 1997;25:951–968.
    pubmed: 9402338
  28. Yeaman MR, Bayer AS. Antimicrobial peptides from platelets.. Drug Resist Updat 1999;2:116–126.
    pubmed: 11504479

Citations

This article has been cited 3 times.
  1. Mollabashi M, Klopfer A, Lunardon T, Darzenta N, Davis E, Murray M, Sumner SM, Naskou MC. Plasma and complement proteins are essential for the antimicrobial activity of canine platelet lysate. Front Vet Sci 2025;12:1605649.
    doi: 10.3389/fvets.2025.1605649pubmed: 40666728google scholar: lookup
  2. Egli P, Boone L, Huber L, Higgins C, Gaonkar PP, Arrington J, Naskou MC, Peroni J, Gordon J, Lascola KM. Pilot study characterizing a single pooled preparation of equine platelet lysate for nebulization in the horse. Front Vet Sci 2024;11:1488942.
    doi: 10.3389/fvets.2024.1488942pubmed: 39726585google scholar: lookup
  3. Khatibzadeh SM, Dahlgren LA, Caswell CC, Ducker WA, Werre SR, Bogers SH. Equine bone marrow-derived mesenchymal stromal cells reduce established S. aureus and E. coli biofilm matrix in vitro. PLoS One 2024;19(10):e0312917.
    doi: 10.1371/journal.pone.0312917pubmed: 39480794google scholar: lookup
Subscribe to our newsletter
Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.